Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
The Motley Fool
by newsfeedback@fool.com (Jonathan Ponciano)February 23, 2026
AI-Generated Deep Dive Summary
Baker Bros. Advisors LP has significantly increased its stake in Praxis Precision Medicines (NASDAQ: PRAX) by acquiring 437,000 shares worth approximately $81.38 million during the fourth quarter of 2025. This move comes as Praxis' stock price surged over 300% in just one year, reflecting strong investor confidence in the biotechnology company's growth potential. The transaction brought the total post-trade stake to 1,126,488 shares, with the quarter-end valuation rising by $295.48 million due to both trading activity and stock price movements.
Praxis Precision Medicines, based in Boston, specializes in developing therapies for neurological and psychiatric disorders, addressing significant unmet medical needs in the central nervous system (CNS) market. The company’s pipeline includes differentiated clinical candidates targeting neuronal imbalances, supported by strategic collaborations and licensing agreements. This focus on innovative treatments positions Praxis as a potential leader in the CNS therapeutics sector.
The investment highlights the growing interest in biotechnology stocks, particularly those with strong pipelines addressing unmet medical needs. Baker Bros.' significant purchase underscores the perceived growth and profitability opportunities in Praxis. For investors, this move signals confidence in Praxis' ability to deliver first-in-class or best-in-class treatments, aligning with its mission to transform patient lives through groundbreaking therapies.
Overall, the buy reflects a strategic play for long-term gains in the biotech sector. With shares soaring over 300% year-over-year, Praxis appears poised for continued growth, making it an attractive option for investors seeking high-potential opportunities in the finance and healthcare spaces.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/23/2026